SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 27th, 2024 • Biofrontera Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of November 21, 2024, by and among Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITY AGREEMENTSecurity Agreement • November 27th, 2024 • Biofrontera Inc. • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of November 21, 2024 (this “Agreement”), is among Biofrontera, Inc., a Delaware corporation (the “Company”), and each Subsidiary of the Company which shall become a party to this Agreement by execution and delivery of the form annexed hereto as Annex A and the Subsidiary Guaranty annexed thereto (each such Subsidiary, a “Guarantor” and together with the Company, the “Debtors”), Rosalind Advisors, Inc., as collateral agent (the “Collateral Agent”) for the holders of the Company’s Secured Convertible Notes issued at or about November 22, 2024, in the original aggregate principal amount of $4,200,000 and such other of the Company’s secured notes which may be issued to the Lenders in the future (collectively, the “Notes”) (such holders collectively, the “Secured Parties”).
